Skip to main content
United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
358.93
-7.46 (-2.04%)
At close: Jan 17, 2025, 4:00 PM
365.00
+6.07 (1.69%)
After-hours: Jan 17, 2025, 4:55 PM EST

United Therapeutics Revenue by Segment
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
Tyvaso
1.56B 1.45B 1.37B 1.23B 1.13B 1.06B 939.40M 873.00M
Tyvaso Growth
38.18% 36.87% 45.60% 41.32% 41.17% 50.25% 43.09% 43.70%
Remodulin
518.70M 521.50M 501.40M 494.80M 502.20M 485.10M 489.90M 500.20M
Remodulin Growth
3.29% 7.50% 2.35% -1.08% 1.25% -4.39% -4.91% -2.63%
Orenitram
410.60M 389.40M 377.40M 359.40M 351.10M 346.60M 330.50M 325.10M
Orenitram Growth
16.95% 12.35% 14.19% 10.55% 9.17% 8.55% 4.42% 6.21%
Unituxin
225.40M 215.60M 208.20M 198.90M 181.40M 176.20M 176.40M 182.90M
Unituxin Growth
24.26% 22.36% 18.03% 8.75% -7.54% -14.22% -17.57% -9.59%
Adcirca
25.90M 26.20M 28.00M 28.90M 32.50M 35.90M 38.80M 41.30M
Adcirca Growth
-20.31% -27.02% -27.84% -30.02% -16.67% -16.32% -30.84% -26.12%
Other
15.60M - 12.00M 8.30M 8.20M - 6.30M 13.80M
Other Growth
90.24% - 90.48% -39.86% - - -37.00% -

Revenue by Geography
Period Ending Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020
United States
2.62B 2.49B 2.37B 2.20B 2.08B 2.00B 1.87B 1.81B
United States Growth
25.96% 24.63% 26.68% 21.39% 19.78% 21.06% 15.70% 15.98%
International
136.30M 129.50M 124.30M 125.30M 124.30M 115.30M 107.30M 122.20M
International Growth
9.65% 12.32% 15.84% 2.54% 0.65% -17.82% -27.79% 0.74%
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.